Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it will be presenting at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年6月22日)-Nova Mentis生命科學公司(CSE：NOVA)(FSE：HN3Q)(OTCQB：NMLSF)(“Nova”或“公司”)，一家生物技術公司和一流的以裸蓋菇素為基礎的療法和神經炎性疾病輔助診斷的全球領導者高興地宣佈，它將在H.C.Wainwright首屆精神衞生年會：神經精神病學、迷幻藥及其他2022年6月27日。
The NOVA presentation is titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome.
Nova演示文稿的標題是：一種新的裸蓋菇素治療脆性X綜合徵。
NOVA has filed a patent to protect the novel psilocybin microdose therapeutic approach to treatment of autism spectrum disorder (ASD) and especially fragile X syndrome (FXS), the largest genetic cause of ASD. This breakthrough psilocybin treatment preclinical data will be presented at the HCW conference.
Nova已經申請了一項專利，以保護新的裸蓋菇素微劑量治療方法，用於治療自閉症譜系障礙(ASD)，特別是脆性X綜合徵(FXS)，這是ASD的最大遺傳原因。這一突破性的裸蓋菇素治療臨牀前數據將在HCW會議上公佈。
The Company's patent is titled: Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivativesm; RNA Diagnostic Index to Measure Drug Treatment Response.
該公司的專利名稱為：精神活性色胺類藥物對神經系統疾病的診斷、監測和治療；衡量藥物治療反應的RNA診斷指數.
"NOVA is looking forward to advancing the discussion around the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS)," says Dr. Marvin S. Hausman, Chairman of NOVA's Scientific Advisory Board. "Future government regulatory plans, based on our proprietary psilocybin drug (NM-1001) positive preclinical study data, will also be discussed."
諾華公司科學顧問委員會主席馬文·S·豪斯曼博士説：“諾華公司期待着推進有關口服微劑量裸蓋菇素治療自閉症譜系障礙(ASD)和脆性X綜合徵(FXS)的潛力的討論。還將討論基於我們的裸蓋菇素專利藥物(NM-1001)陽性臨牀前研究數據的未來政府監管計劃。“
Dr. Hausman's presentation will be available on-demand starting at 7:00 a.m. EST on June 27, 2022. Click here to register for the conference and schedule a one-on-one meeting with Dr. Hausman.
豪斯曼博士的演示文稿將從上午7點開始按需提供。美國東部時間2022年6月27日。點擊這裏註冊參加會議，並安排與豪斯曼博士一對一的會面。
About Nova Mentis Life Science Corp.
關於Nova Mentis生命科學公司
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司，在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。
Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
我們的目標是診斷和治療那些沒有滿足醫療需求的令人衰弱的慢性疾病，如自閉症譜系障礙(ASD)和FXS。
For further information on the Company, please visit or email info@novamentis.ca.
欲瞭解更多有關公司的信息，請訪問或發送電子郵件至info@novamentis.ca。
On Behalf of the Board
我謹代表董事會
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
威爾·拉斯坎，總裁兼首席執行官
Nova Mentis生命科學公司
Phone: 778-819-0244
Toll Free: 1-833-542-5323
電話：778-819-0244
免費電話：1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
推特：@novamentislsc
Instagram：@novamentislsc
臉書：@novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述，通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在”和類似的表述，或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。